SecBot SecBot
SECBOTREPLAY Home › Report › REPL

REPL · Replimune filed Amendment No

Replimune Group, Inc. · S-3/A filed Jul 24, 2026 at 16:57 ET

At the news

BEARISHIMPACT 6/10

S-3/A filed Jul 24, 2026 at 16:57 ET

Replimune filed Amendment No. 1 to its S-3 shelf registration, enabling Baker Brothers affiliates to resell up to 25,103,489 shares (≈30% of current outstanding, including pre-funded warrants). The company receives no proceeds and has a going-concern warning with cash runway only through Q1 2027, while the FDA decision on the RP1 BLA is due August 2, 2026 (advisory committee July 30). This registration overhang adds downside risk ahead of the binary catalyst.

  • 25,103,489 shares registered for resale by Baker Bros Life Sciences and 667, L.P. (Baker Bros. Advisors LP), including 14,058,153 shares issuable upon exercise of pre-funded warrants with nominal exercise prices.
  • The selling stockholders beneficially own 25.94% of the company's shares as of March 31, 2026.
  • Company's independent auditors included a going-concern explanatory paragraph in the FY2026 10-K; cash, equivalents and short-term investments will fund operations only into Q1 2027.
  • FDA action date for RP1 BLA resubmission (advanced melanoma) is August 2, 2026, with an advisory committee meeting on July 30, 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access